Skip to content

Vor Biopharma VOR Enterprise value

Enterprise value at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$622.06B+50.5%
Amgen logo
AmgenAMGN
$246.43B+9.9%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$109.92B-9.5%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$3.82B+565%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$787.38M+114%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$646.16M+211%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,513%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Calculated from Vor Biopharma’s reported figures.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's enterprise value?
Vor Biopharma (VOR) reported enterprise value of $704.51M in Q1 2026.
How has Vor Biopharma's enterprise value changed year-over-year?
Vor Biopharma's enterprise value increased by 901.9% year-over-year, from $70.32M to $704.51M.
What is the long-term trend for Vor Biopharma's enterprise value?
Over 4 years (2021 to 2025), Vor Biopharma's enterprise value has grown at a -24.6% compound annual growth rate (CAGR), from $331.56M to -$106.89M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.